The Record - for physicians and other health care providers to share with their office staffs Forward to a friend  |  Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com  |  Print entire issue

August 2014

Facility

Enrollment for BCBSM’s new freestanding radiology center network begins Oct. 1

What is a freestanding radiology center?

A freestanding radiology center is a fixed-location or mobile facility that provides non-emergency diagnostic imaging services to ambulatory patients.

FRCs may include both nonhospital and hospital-owned facilities. An FRC doesn’t include doctor offices with imaging services if their primary focus is the management and treatment of their own patients’ conditions.

Mobile facilities are imaging units capable of operating remotely at two or more sites. The sites are authorized by the Michigan Department of Community Health under a contractual agreement. The mobile facilities must visit the sites on a regularly scheduled basis with the imaging technology typically not separate or unattached from the travel vehicle. Portable X-ray suppliers would not qualify as a mobile FRC.

Blue Cross Blue Shield of Michigan is establishing a freestanding radiology center network to recognize and reimburse freestanding providers of diagnostic imaging services.

Eligible hospital and nonhospital-owned FRCs can enroll in the BCBSM Traditional network, beginning Oct. 1, 2014. Enrollment materials will be available on bcbsm.com in late September.

The FRC network will go into effect on Jan. 1, 2015.

All participating FRCs will be considered in-network for PPO members, and out-of-network sanctions will be waived.

Establishing this network will make it easier for BCBSM members to find these providers. It will also help us enhance the provider- and service-related cost transparency information available to our members.

Under this new network, we will:

  • Designate FRCs as a unique provider type.
  • Include FRCs in a provider directory on bcbsm.com and on the Blue Cross and Blue Shield Association® website.
  • List cost information, by procedure, for each of the freestanding radiology centers in the provider directories.

Billing information
Freestanding radiology centers will be reimbursed for all diagnostic imaging services that are covered benefits. The covered benefits must be in compliance with Certificate of Need rules and within the approved scope of practice of the rendering provider.

Diagnostic imaging services performed in freestanding radiology centers will be subject to the current Radiology Management program pre-authorization and privileging requirements.

It’s also important to know that:

  • Freestanding radiology centers must bill all services on a CMS-1500 professional claim form or the electronic equivalent. Freestanding radiology centers will be allowed to bill for the professional or technical component or the full fee, depending on the provided service. 
  • Applicants who are currently enrolled as physician group practices may qualify as freestanding radiology centers. In order to be designated as a FRC, these providers will be asked to terminate their current provider identification number and enroll under a new PIN. The existing National Provider Identifier will be mapped to the new FRC record.

Look for more information about our freestanding radiology center network in future Record articles.


Preauthorization changes to Radiology Management Program become effective Jan. 1, 2015

We’re notifying you of two upcoming changes to our PPO Radiology Management Program, administered through AIM Specialty Health. Starting Jan. 1, 2015, we will:

  1. Require preauthorization for the following cardiac imaging procedures:
    • Stress echocardiography
    • Transesophageal echocardiography
    • Resting transthoracic echocardiography
    • These services do not require preauthorization today, either in the office or in a hospital outpatient location
  2. Enforce preauthorization for radiological procedures that are part of the Radiology Management Program and are performed in hospital outpatient locations.
    • Today, claims for services performed in the office location are adjudicated based on the results of the preauthorization process. If preauthorization has not been obtained for the service, the service is rejected and the provider is responsible for the charges.
    • After Jan. 1, 2015, hospital outpatient and professional services performed in the outpatient hospital setting — without required authorization — will be denied as a provider liability. Once this change becomes effective, we will no longer issue quarterly hospital-specific compliance letters and related reports.

Standard PPO Radiology Management Program guidelines apply to both these changes.

We’ll provide additional details in The Record later this year. In the meantime, contact your provider consultant if you would like more information.


New requirements to take effect for facilities submitting BCBSM, FEP® adjustment claims

We’re working to fully automate the process facilities use to submit Blue Cross Blue Shield of Michigan and Federal Employee Program adjustment claims by early 2015.

Our goal is to:

  • Improve the accuracy of 835 remittances.
  • Speed up claims processing time.
  • Reduce the time spent on manual adjustments.
  • Reduce facilities’ account receivables.

To prepare for the transition, new requirements are expected in November 2014 for:

  • Late charges (facility type of bill XX5)
  • Replacement claims (facility type of bill XX7)
  • Void and cancel claims (facility type of bill XX8)

When billing late charge TOB XX5 claims, you should only report the charges for the additional services that weren’t on the original claim. If you’re replacing the original claim, all charges should be reported with TOB XX7, whether it was originally paid, rejected or applied to member cost sharing.

All TOB XX7 and XX8 claims will require the 14- or 17-digit Internal Control Number of the original claim. ICNs are reported with a qualifier of F8 in the REF segment of Loop 2300 in 837 claim transactions.
 
Claims submitted without the 14- or 17-digit ICN will be rejected by the Electronic Data Interchange Department using a 277CA report or transaction. If the claim was submitted with an ICN, it may still reject on a voucher if the processing system is unable to locate a match.

For questions regarding electronic 837 transactions, contact the EDI Helpdesk at 1-800-542-0945. For assistance with billing guidelines, contact your BCBSM provider consultant.


Reminder: Hospital transfer policy

We’d like to remind you of Blue Cross Blue Shield of Michigan’s policy on transferring a patient from one hospital to another. When patients are discharged or transferred to another hospital, please indicate the appropriate discharge disposition as follows:

  • 02 (Discharged/transferred to another short-term general hospital)

    or
  • 07 (Left against medical advice or discontinued care). 

You would enter the discharge disposition on the UB-04 claim form in locator 17 (Patient Discharge Status). The transferring hospital should receive full payment only when the patient’s length of stay meets or exceeds the maximum number of days allowed under the diagnosis related group assigned to the admission.

If a patient is transferred to a second hospital prior to using all days allowed at the first hospital, the transferring hospital should receive only a per diem payment based on the length of stay.

The Blues review paid claims from the previous year to identify patients who were discharged or transferred to another acute care facility. You will receive a letter if we identify claims that may be transfers. If you agree, we’ll adjust your payment. If you disagree, you’ll need to follow the directions on the letter and send in your documentation. Either way, you’ll receive a letter notifying you of our decisions.

For multiple transfers, you may want to refer to the article in the January 2010 Record.


Do not resubmit claims involved in audits

Blue Cross Blue Shield of Michigan is asking providers not to resubmit claims that are involved in our audits. This includes any inpatient or outpatient facility audits including:

  • Readmissions
  • Diagnosis related group
  • Catastrophic cost outliers
  • Transfers
  • Focus
  • Emergency room
  • High dollar
  • Hospital physical therapy, occupational therapy and speech language pathology
  • Ambulatory surgery facility
  • Freestanding outpatient physical therapy facilities
  • End stage renal disease
  • Skilled nursing facility
  • Home health care
  • Hospice

Once you receive a letter notifying you of an audit, including a patient listing, don’t adjust these claims any further. Please let your billing and finance departments know which claims are being audited so they won’t submit any further claims unless you’re notified by the Blues to do so.

Catastrophic cost outlier claims have an additional exception; please see the article in the December 2011 Record. These claims can only have charges rebilled up to 30 days prior to the audit.

Rebilling charges are time-consuming and can create additional problems once the audit process is complete and claims are sent for adjustment.

For more information, please contact your provider consultant.


Reminder: Statewide facility and professional training

We’d like to remind you that training opportunities will take place this summer at five remaining locations around the state.

For information on the facility and professional Upper Peninsula training sessions, see the June Record article. For information on other professional classes in the Lower Peninsula, see the May Record article.

To register for training:

  • Send an email to Jeff Holzhausen at JHolzhausen@bcbsm.com.
  • For the professional class in the UP, in the subject line, type "RMRA Marquette."
  • For the facility class in the UP, type "Facility Marquette" in the subject line.
  • For professional classes in the Lower Peninsula, in the subject line, type "RMRA/Stars" and indicate the city where you want to attend the class.
  • In the body of the email message, put the date of the class you want to attend and the names and number of attendees expected from your facility.

You’ll receive a confirmation within 72 hours of registering. It’s important that you register so we have an accurate headcount for lunch.

The Blues will provide continuing education credits through the AAPC. For more information, contact your provider consultant.


All Providers

BlueCard® program: Learn the basics

We want to improve your experience with the BlueCard program. So this month we’re launching a series of articles that will provide you with important information about the program, including a look at the online tools available to help you handle claims for members enrolled outside of Michigan. Our first article gives you an overview of BlueCard and how it works.

What is BlueCard?
BlueCard is a national program that allows members of a Blue plan to receive health care services while traveling or living in another Blue plan's service area. The program links participating health care providers with independent Blue Cross and Blue Shield plans across the U.S. and in more than 200 countries and territories worldwide.

The BlueCard program lets you submit claims for members from other Blue plans, including international ones, directly to Blue Cross Blue Shield of Michigan. Your claim is routed to the appropriate plan based on the member’s three-letter alpha prefix, which is visible on their Blue Cross ID card.

How does BlueCard work?
To make sure that claims processing is consistent among plans, the Blue Cross and Blue Shield Association® developed “host” and “home” definitions to distinguish plan types and a list of responsibilities for each one.

For services received in Michigan, our BCBSM plan would be considered the host plan. We would be responsible for:

  • Servicing Michigan providers
  • Receiving and pricing their claims
  • Routing claims with the pricing data to the member’s home plan
  • Paying providers

The home plan is the plan where a member is enrolled. The home plan is responsible for:

  • Servicing the member
  • Determining eligibility
  • Confirming member benefits per their contract
  • Determining authorization requirements for provider services
  • Determining medical and benefit policy as it applies to the services reported on claims 
  • Determining the coordination of benefit policy when a claim is reported for secondary or tertiary benefits. 

You can find more information about the BlueCard program in our provider manuals located on web-DENIS. To find the manuals, log in to web-DENIS and click on BCBSM Provider Publications and Resources.

Do you have article ideas for our BlueCard series?
We want to hear from you if there’s specific information about the BlueCard program that you’d like to see featured in The Record. If you have any suggestions or any questions about the program, contact your provider consultant or send an email to ProvComm@bcbsm.com. Put “BlueCard series” in the subject line.

Be sure to check out next month’s issue of The Record to learn more about BlueCard.


Professional phone line hours changing for West Michigan Provider Servicing

To better align provider servicing call centers across the state, the professional phone line hours of West Michigan Provider Servicing (formerly West MI Provider Inquiry) are changing, effective Sept. 1.

The new hours for West Michigan professional servicing will be 8:30 a.m. to 5 p.m. Their call center continues to be open Monday through Friday. The phone number remains 1-800-255-1878.

West Michigan’s facility call center hours continue to be 7:30 a.m. to 4 p.m. The phone number is 1-800-643-2583.

Both areas are closed for lunch from 12 to 1 p.m.


Register today to attend webinar on estrogen utilization in the 65 and older population

Blue Cross Blue Shield of Michigan is conducting a series of educational webinars for health care providers to discuss two pharmacy-related Medicare star measures — high-risk medications in older adults and the use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertensive diabetics.

The next webinar, to be held on Aug. 27, 2014, at 8 a.m., will address the use of estrogen utilization in the 65 and older population. It will be conducted by Patricia A. Ferguson, M.D., F.A.C.O.G, a board-certified OB/GYN who practices in Bingham Farms and is affiliated with Providence Hospital. The 30-minute webinar will be followed by a question-and-answer session.

To register, email SEprofessionaleducationregistration@bcbsm.com. Include the date, time and name of the class you wish to attend, as well as your national provider identifier. You’ll receive a confirmation email within 72 hours of registering. Instructions on how to access the webinar via WebEx will be sent in the confirmation email or prior to the webinar.

If you have questions about the content of the webinar or the registration process, contact Lawrence Beal at 313-225-8981.

If you have technical issues or questions, call the BCBSM Web support help desk at 1-877-258-3932.

Additional webinars in this series will be announced in future issues of The Record and on web-DENIS.


Keep in mind these coding tips to improve medical record documentation

According to the Centers for Disease Control and Prevention, one in every three adults has hypertension and only half of those adults have it under control. If left uncontrolled for too long, hypertension can damage the heart, kidneys and other organs.

The hypertension table in the ICD-9-CM Alphabetic Index is the first point of reference when coding hypertension. It classifies hypertension by type, primary or secondary, and by nature, benign, malignant or unspecified. There are codes which are used for reporting hypertension in its simple vascular state, without manifestations, and combination codes that illustrate the affect of hypertension on other organs. This allows providers to communicate the complexity of their patient’s condition to the greatest specificity — whether the condition exists alone or with other diseases.

Coding tips for hypertension
Here are common codes for hypertension:

  • Primary, or essential, hypertension is considered idiopathic — occurring without apparent cause. Code categories 401 to 404 are used for primary hypertension.
  • Secondary hypertension is due to an underlying cause and is reported with codes from category 405.
  • Documentation of hypertension should also specify if it’s benign or malignant:
    • According to the National Institutes of Health, malignant hypertension is defined as high blood pressure that comes on suddenly and quickly. Malignant hypertension often causes organ damage. Other terms for malignant hypertension include accelerating or necrotizing.
    • Benign hypertension is mild to moderate elevation in blood pressure of prolonged or chronic duration without target organ damage.
    • If hypertension is not documented as benign or malignant, it’s reported as unspecified hypertension (401.9). Coders can’t determine if hypertension is benign or malignant; it must be documented in the progress note by the provider.
  • Documentation should indicate hypertension, benign, or hypertension, malignant. Documentation that states only elevated or high blood pressure could be misinterpreted as transient or incidental hypertension.
  • Use of the words controlled or uncontrolled to describe hypertension refers to the status of the condition, not whether it’s benign or malignant. Status indicates if it’s responding to medication, diet or other therapy, not if it’s benign or malignant. For example, documentation that states hypertension, controlled should be coded as 401.9 (hypertension, unspecified), not 401.1 (malignant hypertension).   
  • Documentation that indicates elevated or high blood pressure, or borderline hypertension, but doesn’t state a diagnosis of hypertension, is reported with 796.2 (elevated blood pressure reading with no mention of hypertension). 

Hypertension and correct coding
There are three codes for primary (essential) hypertension in its most simple vascular state:

Code

Title

401.0

Malignant hypertension

401.1

Benign hypertension

401.9

Unspecified hypertension

Hypertensive heart disease
Hypertension may increase the workload of the left ventricle of the heart due to the higher systemic vascular resistance. This can result in hypertrophy of the heart or combined hypertrophy and dilation, also known as heart disease. 

When documentation indicates a cardiac condition is due to hypertension, caused by hypertension or hypertensive, report a combination code from category 402. Providers must establish causality in the documentation. Causality can’t be assumed.

Code

Title

402.00

Malignant hypertensive heart disease, without heart failure

402.01

Malignant hypertensive heart disease, with heart failure

402.10

Benign hypertensive heart disease, without heart failure

402.11

Benign hypertensive heart disease, with heart failure

402.90

Unspecified hypertensive heart disease, without heart failure

402.91

Unspecified hypertensive heart disease, with heart failure

Conditions classifiable to category 402 are indicated in the subterms and include cardiomyopathy, myocarditis, myocardial degeneration, cardiovascular disease, cardiomegaly, heart disease and conditions from 429.81 to 420.89 (other ill-defined heart diseases).

Additional codes from category 428 may also be documented and reported for the type of heart failure. Hypertensive heart disease doesn’t include conditions classifiable to ischemic heart disease (410 to 414); however, these might also be documented in the medical record and should be coded separately. 

Hypertensive chronic kidney disease
According to the National Kidney Foundation, hypertension is the leading cause of chronic kidney disease. It can also be a complication of CKD, and the association between hypertension and CKD is so strong that ICD-9-CM presumes a cause-and-effect relationship between the two conditions. 

Code

Title

403.0x

Malignant hypertensive CKD

403.1x

Benign hypertensive CKD

403.9x

Unspecified hypertensive CKD

Fifth digit: 0 — CKD stage I through IV, or unspecified. 
                  1 — CKD stage V or end-stage renal disease.

A code from category 585 should also be used to document the stage of CKD.

Only chronic kidney conditions classified to category 585 or 587 can be reported with the hypertensive CKD codes. There isn’t an assumed causal relationship between hypertension and acute renal failure, which usually develops as the result of an event such as dehydration, major blood loss or the affect of medicine, and it’s often reversible. In contrast, chronic kidney disease is caused by the affects of hypertension or other diseases over a long period of time.    

Hypertensive heart and chronic kidney disease
The kidneys play an important role in regulating blood pressure. But when they develop disease, blood pressure increases and the likelihood of heart problems increases, too. Due to their interactive nature, category 404 combines three conditions: heart disease, hypertension and CKD. As previously indicated, a relationship between CKD and hypertension can be assumed, but documentation must indicate a causal relationship between hypertension and heart disease. 

Code

Title

404.0x

Hypertensive heart and chronic kidney disease, malignant

404.1x

Hypertensive heart and chronic kidney disease, benign

404.9x

Hypertensive heart and chronic kidney disease, unspecified

Fifth digit: 0 – without heart failure and with CKD stage I – IV, or unspecified
                  1 – with heart failure and with CKD stage I – IV, or unspecified
                  2 – without heart failure and with CKD stage V or end stage renal disease
                  3 – with heart failure and chronic kidney disease stage V or end stage renal disease

Additional codes should be added to indicate the type of heart failure and stage of CKD. 

Secondary hypertension
Secondary hypertension is coded using category 405. It’s defined as high arterial blood pressure due to another underlying cause or primary disease, such as renal disorder, central nervous system disorders, endocrine or vascular diseases. A code should be reported for the type of secondary hypertension and also a code for the underlying etiology. 

Hypertension may contribute or accelerate the development of many other conditions. Because ICD-9-CM doesn’t provide combination codes for every condition, assign a code for each individual condition to communicate the complexity of a patient’s condition.

Be sure to check out next month’s edition of The Record, which will include an article about coding tips for chronic kidney disease.

None of the information included in this article should be considered legal advice. As such, it is the provider’s responsibility to ensure that all coding and documentation are done in accordance with applicable state and federal laws and regulations.


Blues highlight medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM Changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

20999, 50250, 50542, 50593

Experimental procedures
0340T, 19105

Basic Benefit and Medical Policy
The Cryosurgical Ablation of Renal and Bone Tumors Policy has been established. It is effective Nov. 1, 2014.

The safety and effectiveness of cryosurgical ablation to treat localized renal cell carcinoma have been established. It may be considered a useful therapeutic option when indicated.

Also, the safety and effectiveness of cryosurgical ablation to palliate pain in patients with osteolytic bone metastases have been established. It may be considered a useful therapeutic option when indicated.

And the safety and effectiveness of cryosurgical ablation to treat osteoid osteoma have been established. It may be considered a useful therapeutic option when indicated.

Cryosurgical ablation as a treatment of benign or malignant tumors of the breast, lung or pancreas is considered experimental. It has not been scientifically demonstrated to improve patient clinical outcomes.

Inclusionary Guidelines
Renal cell carcinoma with no evidence of metastasis and when either of the following criteria is met:

  • The tumor is no more than 4 cm in its greatest dimension, preservation of kidney function is necessary (i.e., the patient has one kidney or renal insufficiency defined by a glomerular filtration rate [GFR] of less than 60 mL/min per m2) and the standard surgical approach (i.e., resection of renal tissue) is likely to substantially worsen kidney function; or
  • The tumor is no more than 4 cm in its greatest dimension and the patient is not considered a surgical candidate.

Cryosurgical ablation to palliate pain in patients with osteolytic bone metastases when all of the following criteria are met:

  1. Patient ≥ age 18 years.
  2. One or two painful bone metastasis lesions, 1-11 cm in size
  3. Patient has failed or is a poor candidate for standard treatments, such as radiation or opioids.
  4. Patient has a pain score ≥ 4 on a scale of 0-10.
  5. Life expectancy is > 2 months.
  6. The lesion is > 1 cm away from the spinal cord, brain, other critical nerve structure or large abdominal vessel, such as the aorta or inferior vena cava, bowel or bladder
  7. The coagulation profile is normal (platelets > 50,000 and INR > 1.5).
  8. The site of the lesion is not at imminent risk of fracture.
  9. Patient must not have a primary musculoskeletal malignancy, lymphoma or leukemia.

Cryosurgical ablation to treat osteoid osteoma when any of the following criteria are met:

  1. Those who have failed medical therapy
  2. Those being considered for surgical resection
  3. Those who have failed previous surgical therapy and have recurrent symptoms or pain

Exclusionary Guidelines
Other indications not noted in the policy.

67027, J7310

Basic Benefit and Medical Policy
Effective Nov. 1, 2013, HCPCS code J7310 may be covered as a standalone item when reported with surgical procedure code *67027.

83993

Basic Benefit and Medical Policy
The clinical utility of fecal calprotectin testing has been established for pediatric patients. It can be a useful option when used as an adjunctive non-invasive test for confirming a diagnosis of inflammatory bowel disease and in determining if an endoscopy may be needed.

Fecal calprotectin testing in non-pediatric patients is considered experimental. Further prospective trials and the establishment of appropriate cut-off values are needed to determine the clinical utility of this testing for non-pediatric patients. This policy is effective March 1, 2014.

Group Variations
Excludes Chrysler, Ford, Delphi and URMBT groups. Payable for General Motors, effective July 1, 2014.

Payment Policy
Not payable in an office location

Inclusionary Guidelines
Established for pediatric patients for diagnosing inflammatory bowel disease

Exclusionary Guidelines

  • Use of fecal calprotectin testing in adults
  • Use of fecal calprotectin testing in asymptomatic pediatric patients as a general screening tool
  • Use of fecal calprotectin testing in pediatric patients as a guide for ongoing management of a patient with IBD
UPDATES TO PAYABLE PROCEDURES

31575, 31579, 92511, 92611, 92612, 92616

Basic Benefit and Medical Policy
Effective Jan. 1, 2012, independent speech language pathologists are payable for the listed procedure codes.

33224-33226

Basic Benefit and Medical Policy
Additional congestive heart failure diagnosis codes are payable for biventricular pacemakers. The payable diagnosis codes are: 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43 and 428.9.

This change does not apply to General Motors, Ford, Chrysler and UAW Retiree Medical Benefits Trust groups.

44705, G0455

Basic Benefit Policy
The safety and effectiveness of fecal microbiota transplant have been established. It is a useful therapeutic option for patients meeting select guidelines.

Group Variations
Payable for GM hourly and salaried enrollees, effective Sept. 20, 2013.

Established procedure
71250

Experimental procedures
0174T, 0175T

Basic Benefit and Medical Policy
The safety and effectiveness of low-dose CT scanning of the lung as a screening tool for lung cancer have been established. It is a useful therapeutic option for patients meeting specific patient selection guidelines.

Routine chest radiographs, including computer-aided detection analysis of the X-ray, for the purpose of screening patients for lung cancer is considered experimental. They have not been shown to improve long-term patient clinical outcomes, effective May 1, 2014.

Group Variations
Excludes Chrysler, Ford, General Motors, Delphi and URMBT groups

Inclusionary Guidelines
Low-dose computed tomography scanning, no more frequently than annually, may be appropriate as a screening technique for lung cancer in individuals who meet all of the following criteria (which are based on the results of the National Lung Screening Trial):

  • Between 55 and 80 years of age
  • History of cigarette smoking of at least 30 “pack years” (A “pack year” is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. A “one-pack year” is the equivalent of 365.24 packs of cigarettes or 7,305 cigarettes.)
  • Currently smoke or have quit within the past 15 years

Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.

Exclusionary Guidelines

  • Low-dose CT scanning as a screening technique for lung cancer in all other situations where the above selection guidelines are not met
  • Routine chest radiographs when used as a screening technique for ruling out lung cancer
A9700

Basic Benefit and Medical Policy
Procedure code A9700 is being removed from processing under the IVT/ Chemo Drugs (IND) category, PHA Service Type (R) for facility.

Procedure code A9700 is an active code and will remain eligible for processing under the radiology category with revenue code 0255 - Pharmacy-Drugs Incident to Radiology.

J7199

Basic Benefit and Medical Policy
Effective March 28, 2014, ALPROLIX™ is considered established as safe and effective for its FDA-approved indication in the United States. It is indicated for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia B.

Inclusionary Guidelines
ALPROLIX™ Coagulation Factor IX (Recombinant) Fc Fusion Protein is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • Control and prevention of bleeding episodes.
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

For the control and prevention of bleeding episodes, the management of bleeding during surgical procedures and for routine prophylaxis in adults and children with hemophilia B.
Payable for:

  • Hemophilia provider network
  • Ambulatory Infusion center (ALPROLIX may only b used at the center. It cannot be sent home with the patient.
  • Specialty pharmacy )
  • Physician’s office

Exclusionary Guidelines
ALPROLIX™ is not indicated for induction of immune tolerance in patients with Hemophilia B.

J7199

Basic Benefit and Medical Policy
Effective Dec. 23, 2013, the FDA approved TRETTEN™, an injectable medicine used to prevent bleeding in adults and children who have congenital factor XIII (FXIII) A-subunit deficiency. TRETTEN™ is man-made and does not contain animal or human materials.

POLICY CLARIFICATIONS

20974, 20975, E0747, E0749

Basic Benefit and Medical Policy
The Inclusionary and exclusionary guidelines for the Bone Growth Stimulation: Electrical Bone Growth Stimulation of the Appendicular Skeleton Policy have been updated. This policy is effective Sept. 1, 2014.

Inclusionary Guidelines
Noninvasive electrical bone growth stimulation is appropriate for the treatment of nonunions of fractures or for congenital pseudoarthroses in the appendicular skeleton. The appendicular skeleton includes the bones of the shoulder girdle, upper extremities, pelvis and lower extremities. The diagnosis of fracture nonunion must meet all the following criteria:

  • At least three months have passed since the date of fracture
  • Serial radiographs have confirmed that no progressive signs of healing have occurred
  • The patient can be adequately immobilized and is of an age likely to comply with non-weight bearing.

Exclusionary Guidelines
All other applications of electrical bone growth simulation, including, but not limited to:

  • The immediate post-surgical treatment after appendicular skeletal surgery
  • Stress fractures
  • The treatment of fresh fractures (A fracture is most commonly defined as “fresh” during the initial seven days after the fracture occurs.)
  • Delayed union (Delayed union is defined as a decelerating healing process as determined by serial X-rays, together with a lack of clinical and radiologic evidence of union, bony continuity, or bone reaction at the fracture site for no less than three months from the index injury or the most recent intervention.)
  • Arthrodesis
  • Failed arthrodesis

81228, 81229, S3870

Basic Benefit and Medical Policy
The safety and effectiveness of chromosomal microarray analysis have been established. It may be considered a useful diagnostic option when indicated for patients meeting specific patient selection criteria. Exclusionary criteria have been updated, effective Sept. 1, 2014.

Inclusionary Guidelines
Chromosomal microarray analysis may be considered established for diagnosing a genetic abnormality in children with apparent nonsyndromic cognitive developmental delay, intellectual disability or autism spectrum disorder, according to accepted Diagnostic and Statistical Manual of Mental Disorders-IV criteria when all of the following conditions are met:

  • Any indicated biochemical tests for metabolic disease have been performed, and results are non-diagnostic
  • FMR1 gene analysis (for Fragile X), when clinically indicated (refer to policy “Genetic Testing for FMR1 mutations (including Fragile X Syndrome), is negative,
  • In addition to a diagnosis of nonsyndromic DD/ID or ASD, the child has one or more of the following:
    • Two or more major** malformations
    • A single major malformation or multiple minor*** malformations, in an infant or child who is also small-for-dates
    • A single major malformation and multiple minor malformations

and

  • The results for the genetic testing have the potential to impact the clinical management of the patient and
  • Testing is requested after the parent(s) have been engaged in face-to-face genetic counseling with a health care professional who has appropriate genetics training and experience.

Note: A malformation refers to abnormal structural development.

**A major malformation is a structural defect that has a significant effect on function of social acceptability. Example: ventricular septal defect or a cleft lip

***A minor malformation is a structural abnormality that has minimal effect on function or societal acceptance. Examples: preauricular ear pit or partial syndactyly (fusion) of the second and third toes

A syndrome is a recognizable pattern of multiple malformations. Syndrome diagnoses are often relatively straightforward and common enough to be clinically recognized without specialized testing. Examples include Down syndrome, neural tube defects and achondroplasia. However, in the very young, or in the case of syndromes with variable presentation, confident identification may be difficult without additional testing.

Exclusionary Guidelines

  • Chromosomal microarray analysis is considered experimental in all other cases of suspected genetic abnormality in children with developmental delay, intellectual disability or autism spectrum disorder.
  • Chromosomal microarray analysis to confirm the diagnosis of a disorder or syndrome that is routinely diagnosed based on clinical evaluation alone is not medically necessary.
  • Panel testing using next-generation sequencing is considered experimental in all cases of suspected genetic abnormality in children with developmental delay, intellectual disability or autism spectrum disorder.
  • Chromosomal microarray analysis is considered experimental for prenatal genetic testing. CMA genetic testing of products of conception following pregnancy loss or idiopathic recurrent pregnancy loss.

83516

Basic Benefit and Medical Policy
The Antigen Leukocyte Antibody Test is considered experimental. There is a lack of published research on the diagnostic accuracy of the test; therefore, it is not possible to determine the sensitivity, specificity or predictive value of the test compared with alternatives. This policy is effective Sept. 1, 2014.

Multiple codes

Coverage of Routine Services Associated with Clinical Trials

Basic Benefit and Medical Policy
The Blue Cross physicians on the Medical Policy Committee reviewed the Coverage of Routine Services Associated with Clinical Trials policy and determined that the cost of routine services of qualifying clinical trials, as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in approved clinical trials, will be covered. Covered clinical trials may include Phase II, III and IV.

The cost of routine services during Phase I clinical trials are only covered when the purpose is for therapeutic intent. This policy is effective Jan. 1, 2014.

Note: Expanded clinical trial coverage does not apply to all members. Always check member eligibility and benefits before providing services.

Inclusionary Guidelines

  • Costs of routine services associated with clinical trials include all items and services that are otherwise generally available to members receiving an established medical treatment. These include items or services, medical in nature, that are provided in either the experimental or the control arm of a clinical trial:
    • Items or services that are typically provided absent a clinical trial (e.g., labs, X-rays, etc.)
    • Items or services required solely for the provision of the investigational item or service (e.g., administration of a non-covered chemotherapeutic agent). The clinically appropriate monitoring of the effects of the item or service, or the prevention of complications
    • Items or services needed for reasonable and necessary care arising from the provision of an investigational item or service; in particular, for diagnosis or treatment of complications
  • For a clinical trial to qualify for coverage of routine costs, the following requirements must be met:
    • The subject or purpose of the trial must be the evaluation of an item or service that falls within a benefit category (e.g., physicians’ services, durable medical equipment, diagnostic tests) and is not normally excluded from coverage (e.g., cosmetic surgery)
    • Trials of therapeutic interventions must enroll patients with diagnosed disease rather than healthy volunteers. Trials of diagnostic interventions may enroll healthy patients in order to have a proper control group.

Note: The requirements above are insufficient by themselves to qualify a clinical trial for coverage of routine costs. Clinical trials should also have all the following characteristics:

  • The principal purpose of the trial is to test whether the intervention potentially improves the participants’ health outcomes and not just to test the item’s safety.
  • The trial is well-supported by available scientific and medical information or it is intended to clarify or establish the health outcomes of interventions already in common clinical use.
  • The trial does not unjustifiably duplicate existing studies.
  • The trial design is appropriate to answer the research question being asked in the trial.
  • The trial is sponsored by a credible organization or individual capable of executing the proposed trial successfully.
  • The trial complies with federal regulations relating to the protection of human subjects.
  • All aspects of the trial are conducted according to the appropriate standards of scientific integrity.

All requests for member participation in a clinical trial must include the appropriate supporting documentation, including:

  • A complete description of the clinical trial, including the phase of the trial
  • Name of the sponsoring organization (NIH, CDC, etc.)
  • Patient selection criteria
  • Protocol guidelines
  • Patient history, including previous treatment therapies
  • Appropriate supporting medical literature

Exclusionary Guidelines

  • Routine services for clinical trials that do not meet policy guidelines as defined above
  • Services that are not covered in an applicable member benefit certificate or rider
  • The investigational item or service itself
  • Individual device exemption with Category A FDA approval
  • Items and services provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the patient (e.g., monthly CT scans for condition usually requiring only a single scan)
  • Items and services customarily provided by the research sponsors free of charge for any enrollee in the trial
  • Phase I clinical trials whose primary purpose is not for therapeutic intent (e.g., prolongation of life, shrinkage of tumor, or improved quality of life, even in absence of cure or dramatic improvement of a condition)

Note: Phase IV clinical trials are performed after the product is released. A specific product or service is covered unless there is a medical policy to the contrary. Data collection, data analysis and other costs for the Phase IV trial are not covered.

EXPERIMENTAL PROCEDURES

0337T

Basic Benefit and Medical Policy
Endothelial function testing using noninvasive techniques is not established. While these services may be safe, their effectiveness in this clinical indication has not been scientifically determined. Therefore, endothelial function testing is considered experimental. This policy is effective Sept. 1, 2014.

0342T

Basic Benefit and Medical Policy
The use of selective HDL dilapidation and plasma reinfusion for the treatment of coronary artery disease or acute coronary syndrome is considered experimental. There is insufficient evidence to permit conclusion on health outcomes and this therapy is not FDA-approved for the treatment of coronary artery disease or acute coronary syndrome. This policy is effective Sept. 1, 2014.

81599
(Unlisted code may be reported)

Basic Benefit and Medical Policy
Genetic testing for molecular markers in fine needle aspirates and the use of a gene expression classifier in fine-needle aspirates of the thyroid is considered experimental, effective Sept. 1, 2014. There is insufficient evidence to support the efficacy of these tests in improving patient clinical outcomes.

GROUP BENEFIT CHANGES

Glaziers Local 826 Health and Welfare Fund

Effective July 1, 2014, Medicare-eligible retirees of the Glaziers Local 826 Health and Welfare Fund will have Blue Cross Blue Shield of Michigan’s Medicare Advantage PPO plan, Medicare Plus BlueSM Group PPO for their medical, surgical and prescription drug benefits. The group number is 60649 with suffix 600. You can identify members by the XYL prefix on their ID cards, like those of other Medicare Plus Blue Group PPO plans.

For information about our Medicare Advantage PPO plan, go to bcbsm.com/provider/ma.

Village of Kalkaska

Effective July 1, 2014, Medicare-eligible retirees of the Village of Kalkaska will have Blue Cross Blue Shield of Michigan’s Medicare Advantage PPO plan, Medicare Plus BlueSM Group PPO for their medical, surgical and prescription drug benefits. The group number is 60667 with suffix 600. You can identify members by the XYL prefix on their ID cards, like those of other Medicare Plus Blue Group PPO plans.

For information about our Medicare Advantage PPO plan, go to bcbsm.com/provider/ma.


Navigating the electronic Record

As part of our efforts to make it easier to do business with us, we’d like to offer some tips for using the electronic Record.

Understanding the format

  • The upper portion of the newsletter features up to four articles that relate to the main area of interest you chose when you subscribed to the newsletter (for example, Professional, Facility, DME). If there are no articles in the issue pertaining to your main area of interest, we’ll feature a few articles from our “All providers” section. This is also the version we post to bcbsm.com.
  • The bottom portion of the newsletter serves as an interactive index, listing the headlines for all the articles in the issue and giving you access to them.

Printing The Record or individual articles

  • You can print individual articles in The Record by clicking on the headlines below the gold bar that reads “For the Record” and then clicking on Print this article at the top of the newsletter.
  • If you want to print all the articles in the newsletter, click on the Print entire issue link in the upper right-hand corner of the newsletter’s front page.
  • Keep in mind that you may not need to access or print all the articles in the newsletter each month. Check out the list of headlines in the bottom section of the newsletter to determine which articles are important to you. For example, if your work location is a doctor’s office, you may not be interested in the articles in the Facility section.

Forwarding The Record

  • You can easily forward The Record by using the Forward to a Friend linkat the top of the front page.
  • If you’re reading an article you’d like to share, you can click on the Forward to a Friend link at the top of the article.

Accessing The Record online

  • You can quickly access current and past issues of the newsletter, dating back to January 2010, along with an index, on The Record Archive.
  • You can also access the newsletter via web-DENIS by clicking on BCBSM Provider Publications and Resources from the web-DENIS home page. Issues in this archive go back to March 1998.

Subscribing to The Record,
You can subscribe to the electronic Record or invite a colleague to subscribe by clicking here or on the Subscribe link at the top of each page of the newsletter.

Customizing your subscription
As part of the subscription process, you’ll be asked to indicate your main area of interest. You may choose from these topics:

  • All providers
  • Professional
  • Facility
  • Pharmacy
  • Medicare Advantage
  • DME
  • Vision
  • Auto groups

Once you select a topic, you’ll generally see about four of those articles in that category highlighted at the top of your email each month. All the articles for that topic — and all other articles in that month’s Record — are listed below the gold bar that says “For the Record.” You’ll see the topics reflected in the colored headings.

You may change your topic selection at any time by clicking on the Update Profile link at the very bottom of The Record email. On this page, you may also update your contact information and email address.


Professionals

Enrollment for BCBSM’s new freestanding radiology center network begins Oct. 1

What is a freestanding radiology center?

A freestanding radiology center is a fixed-location or mobile facility that provides non-emergency diagnostic imaging services to ambulatory patients.

FRCs may include both nonhospital and hospital-owned facilities. An FRC doesn’t include doctor offices with imaging services if their primary focus is the management and treatment of their own patients’ conditions.

Mobile facilities are imaging units capable of operating remotely at two or more sites. The sites are authorized by the Michigan Department of Community Health under a contractual agreement. The mobile facilities must visit the sites on a regularly scheduled basis with the imaging technology typically not separate or unattached from the travel vehicle. Portable X-ray suppliers would not qualify as a mobile FRC.

Blue Cross Blue Shield of Michigan is establishing a freestanding radiology center network to recognize and reimburse freestanding providers of diagnostic imaging services.

Eligible hospital and nonhospital-owned FRCs can enroll in the BCBSM Traditional network, beginning Oct. 1, 2014. Enrollment materials will be available on bcbsm.com in late September.

The FRC network will go into effect on Jan. 1, 2015.

All participating FRCs will be considered in-network for PPO members, and out-of-network sanctions will be waived.

Establishing this network will make it easier for BCBSM members to find these providers. It will also help us enhance the provider- and service-related cost transparency information available to our members.

Under this new network, we will:

  • Designate FRCs as a unique provider type.
  • Include FRCs in a provider directory on bcbsm.com and on the Blue Cross and Blue Shield Association® website.
  • List cost information, by procedure, for each of the freestanding radiology centers in the provider directories.

Billing information
Freestanding radiology centers will be reimbursed for all diagnostic imaging services that are covered benefits. The covered benefits must be in compliance with Certificate of Need rules and within the approved scope of practice of the rendering provider.

Diagnostic imaging services performed in freestanding radiology centers will be subject to the current Radiology Management program pre-authorization and privileging requirements.

It’s also important to know that:

  • Freestanding radiology centers must bill all services on a CMS-1500 professional claim form or the electronic equivalent. Freestanding radiology centers will be allowed to bill for the professional or technical component or the full fee, depending on the provided service. 
  • Applicants who are currently enrolled as physician group practices may qualify as freestanding radiology centers. In order to be designated as a FRC, these providers will be asked to terminate their current provider identification number and enroll under a new PIN. The existing National Provider Identifier will be mapped to the new FRC record.

Look for more information about our freestanding radiology center network in future Record articles.


Preauthorization changes to Radiology Management Program become effective Jan. 1, 2015

We’re notifying you of two upcoming changes to our PPO Radiology Management Program, administered through AIM Specialty Health. Starting Jan. 1, 2015, we will:

  1. Require preauthorization for the following cardiac imaging procedures:
    • Stress echocardiography
    • Transesophageal echocardiography
    • Resting transthoracic echocardiography
    • These services do not require preauthorization today, either in the office or in a hospital outpatient location
  2. Enforce preauthorization for radiological procedures that are part of the Radiology Management Program and are performed in hospital outpatient locations.
    • Today, claims for services performed in the office location are adjudicated based on the results of the preauthorization process. If preauthorization has not been obtained for the service, the service is rejected and the provider is responsible for the charges.
    • After Jan. 1, 2015, hospital outpatient and professional services performed in the outpatient hospital setting — without required authorization — will be denied as a provider liability. Once this change becomes effective, we will no longer issue quarterly hospital-specific compliance letters and related reports.

Standard PPO Radiology Management Program guidelines apply to both these changes.

We’ll provide additional details in The Record later this year. In the meantime, contact your provider consultant if you would like more information.


Reminder: Statewide facility and professional training

We’d like to remind you that training opportunities will take place this summer at five remaining locations around the state.

For information on the facility and professional Upper Peninsula training sessions, see the June Record article. For information on other professional classes in the Lower Peninsula, see the May Record article.

To register for training:

  • Send an email to Jeff Holzhausen at JHolzhausen@bcbsm.com.
  • For the professional class in the UP, in the subject line, type "RMRA Marquette."
  • For the facility class in the UP, type "Facility Marquette" in the subject line.
  • For professional classes in the Lower Peninsula, in the subject line, type "RMRA/Stars" and indicate the city where you want to attend the class.
  • In the body of the email message, put the date of the class you want to attend and the names and number of attendees expected from your facility.

You’ll receive a confirmation within 72 hours of registering. It’s important that you register so we have an accurate headcount for lunch.

The Blues will provide continuing education credits through the AAPC. For more information, contact your provider consultant.


Update: Report national drug code number on professional drug claims for accurate processing

National drug code information is now being used during the claims process to ensure the most accurate and up-to-date pricing for medical drugs, based on the date of service. This applies to all professional offices, clinics and practitioners who provide and bill medical drugs.

Other ancillary providers such as hemophilia network providers, home infusion therapy providers, ambulatory infusion centers, Walgreens Specialty Pharmacy, limited distribution drug specialty pharmacies and durable medical equipment providers are also required to provide the NDC information, as well as the quantity, for claims processing.

Note: Healthcare Common Procedure Coding System and Current Procedural Terminology® codes and quantities are required on all drug claims, as required by HIPAA.

The claims billing submissions information and formats described below can also be found in the provider manuals on web-DENIS.

Finding the NDC and unit of measure
The national drug code is found on a medication's packaging. An asterisk may appear as a placeholder for any leading zeroes. The container label also displays the appropriate unit of measure for that drug. The unit of measure is by weight (grams: GR), volume (milliliter: ML) or count (unit: UN). Each dispensed dose must be converted into one of these, following the manufacturer's unit of measure. International units (F2) must be converted to standard measurements (GR, ML and UN).

  • For drugs that come in a vial in powder form that needs to be reconstituted before administration, bill each vial (UN).
  • For drugs that comes in a vial in liquid form, bill in milliliters (ML).
  • For topical forms of medicine (e.g., cream, ointment, bulk powder in a jar), bill in grams (GR).

Submitting the NDC on claims
Here are some quick tips and general guidelines to assist you with proper submission of valid NDCs and related information on professional claims:

  • The NDC must be submitted along with the applicable HCPCS or CPT code.
  • The NDC must follow the “5digit4digit2digit” format (11 numeric characters with no spaces or special characters). The NDC must be active for the date of service.
  • To submit electronic claims (ANSI 837P), report the following information:

  • Field name

    Field description

    ANSI (Loop 2410) – Ref Desc

    Product ID Qualifier

    Enter “N4” in this field.

    LIN02

    National Drug CD

    Enter the 11-digit NDC assigned to the drug administered.

    LIN03

    NDC Units

    Enter the quantity (number of units) for the prescription drug.

    CTP04

    NDC Unit / MEAS

    Enter the unit of measure of the prescription drug given (GR, UN or ML).

    CTP05-1


  • To submit paper claims, enter the NDC information in field 24 of the CMS-1500 claim form. In the shaded portion of field 24A-24G, enter the qualifier “N4” left-justified, immediately followed by the national drug code. Next, enter the appropriate qualifier for the correct dispensing unit (GR, UN or ML), followed by the quantity and the price per unit, as indicated in the example below.

Here are two claims billing examples:

  • The format for billing should be:
    N4 + NDC code + 3 Spaces+ unit of measure + quantity
    Example: N450242005306   ML50

image 1

  • The format for billing should be:
    N4 + NDC code + 3 Spaces+ unit of measure + quantity
    Example: N468817013450   UN3

image 2 
Keep the following in mind:

  • Reimbursement for discarded drugs applies only to single-use vials. Discarded amounts of drugs in multi-use vials are not eligible for payment.
  • For home infusion therapy and specialty drugs, health care providers must continue to submit claims with national drug code and National Council for Prescription Drug Programs quantities electronically.
  • In previous articles, we mentioned the use of “ME” (milligrams); however, milligrams as a unit of measure will not be accepted.

BCBSM has also expanded the NDC quantity field to house 11 digits, which translates to 8 places before the decimal and 3 places after the decimal to large quantity units. Example: 99999999.999

Clarification: Converting an NDC from 10 to 11 digits
Previously, we communicated the following information about converting a 10-digit NDC to an 11-digit NDC: “If the NDC on the package label has fewer than 11 digits, you must add leading zeroes to total 11 digits.”

We’d like to provide additional details, as follows:

Many national drug codes are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs require a strategically placed zero, depending on the 10-digit format. The following table shows common 10-digit NDC formats indicated on packaging and the appropriate conversion to an 11-digit format. The correctly formatted additional “0” is in bold and underlined in the following examples.

Note: Hyphens indicated below are only used to illustrate the various formatting examples for NDCs. Do not use hyphens when entering the NDC in your claim.

10-digit format on package

10-digit format example

11-digit format

11-digit converted example

4-4-2

0002-7597-01
Zyprexa 10 mg vial

5-4-2

00002-7597-01

5-3-2

50242-040-62
Xolair 150 mg vial

5-4-2

50242-0040-62

5-4-1

60575-4112-1
Synagis 50 mg vial

5-4-2

60575-4112-01

None of the information included in this article should be considered legal advice. As such, it is the provider’s responsibility to ensure that all coding and documentation are done in accordance with applicable state and federal laws and regulations.


DME

Blue Cross to manage additional benefits for State of Michigan retirees and employees

Starting in October 2014, Blue Cross Blue Shield of Michigan will manage the following benefits for State of Michigan members who reside in Michigan:

  • Durable medical equipment
  • Prosthetics and orthotics
  • Medical supplies

This becomes effective on Oct. 1, 2014, for State of Michigan retirees and on Oct. 12, 2014, for active employees.

Here’s how participating DME/P&O providers should handle billing:

  • If the service occurred before the above dates, bill claims to the current vendor DMEnsion.
  • If the services occurred after the above dates, bill claims directly to the members’ local Blue plan.

Other important items to note:

  • Medicare-approved DME providers that provide services to State of Michigan Medicare members can continue to do so after these changes take place in October. Your secondary balance payments will come from Blue Cross instead of DMEnsion.
  • Blue Cross will continue to process State of Michigan DME and P&O claims for members who receive services outside of Michigan through our BlueCard® program. Suppliers that ship equipment or medical supplies to an out-of-state member must participate with the Blue plan in the member’s state in order for the member to receive his or her full benefits.
  • Blue Cross will honor current prescriptions for rental DME and medical supplies as long as the supplier remains the same, the prescription is still valid and the prescription covers the rental period for equipment or supplies being billed.

As a reminder, accrued rental payments for DME items in the vendor program count toward the Blue Cross-approved purchase price.

If you have any questions, contact your provider consultant.


Update: Report national drug code number on professional drug claims for accurate processing

National drug code information is now being used during the claims process to ensure the most accurate and up-to-date pricing for medical drugs, based on the date of service. This applies to all professional offices, clinics and practitioners who provide and bill medical drugs.

Other ancillary providers such as hemophilia network providers, home infusion therapy providers, ambulatory infusion centers, Walgreens Specialty Pharmacy, limited distribution drug specialty pharmacies and durable medical equipment providers are also required to provide the NDC information, as well as the quantity, for claims processing.

Note: Healthcare Common Procedure Coding System and Current Procedural Terminology® codes and quantities are required on all drug claims, as required by HIPAA.

The claims billing submissions information and formats described below can also be found in the provider manuals on web-DENIS.

Finding the NDC and unit of measure
The national drug code is found on a medication's packaging. An asterisk may appear as a placeholder for any leading zeroes. The container label also displays the appropriate unit of measure for that drug. The unit of measure is by weight (grams: GR), volume (milliliter: ML) or count (unit: UN). Each dispensed dose must be converted into one of these, following the manufacturer's unit of measure. International units (F2) must be converted to standard measurements (GR, ML and UN).

  • For drugs that come in a vial in powder form that needs to be reconstituted before administration, bill each vial (UN).
  • For drugs that comes in a vial in liquid form, bill in milliliters (ML).
  • For topical forms of medicine (e.g., cream, ointment, bulk powder in a jar), bill in grams (GR).

Submitting the NDC on claims
Here are some quick tips and general guidelines to assist you with proper submission of valid NDCs and related information on professional claims:

  • The NDC must be submitted along with the applicable HCPCS or CPT code.
  • The NDC must follow the “5digit4digit2digit” format (11 numeric characters with no spaces or special characters). The NDC must be active for the date of service.
  • To submit electronic claims (ANSI 837P), report the following information:

  • Field name

    Field description

    ANSI (Loop 2410) – Ref Desc

    Product ID Qualifier

    Enter “N4” in this field.

    LIN02

    National Drug CD

    Enter the 11-digit NDC assigned to the drug administered.

    LIN03

    NDC Units

    Enter the quantity (number of units) for the prescription drug.

    CTP04

    NDC Unit / MEAS

    Enter the unit of measure of the prescription drug given (GR, UN or ML).

    CTP05-1


  • To submit paper claims, enter the NDC information in field 24 of the CMS-1500 claim form. In the shaded portion of field 24A-24G, enter the qualifier “N4” left-justified, immediately followed by the national drug code. Next, enter the appropriate qualifier for the correct dispensing unit (GR, UN or ML), followed by the quantity and the price per unit, as indicated in the example below.

Here are two claims billing examples:

  • The format for billing should be:
    N4 + NDC code + 3 Spaces+ unit of measure + quantity
    Example: N450242005306   ML50

image 1

  • The format for billing should be:
    N4 + NDC code + 3 Spaces+ unit of measure + quantity
    Example: N468817013450   UN3

image 2 
Keep the following in mind:

  • Reimbursement for discarded drugs applies only to single-use vials. Discarded amounts of drugs in multi-use vials are not eligible for payment.
  • For home infusion therapy and specialty drugs, health care providers must continue to submit claims with national drug code and National Council for Prescription Drug Programs quantities electronically.
  • In previous articles, we mentioned the use of “ME” (milligrams); however, milligrams as a unit of measure will not be accepted.

BCBSM has also expanded the NDC quantity field to house 11 digits, which translates to 8 places before the decimal and 3 places after the decimal to large quantity units. Example: 99999999.999

Clarification: Converting an NDC from 10 to 11 digits
Previously, we communicated the following information about converting a 10-digit NDC to an 11-digit NDC: “If the NDC on the package label has fewer than 11 digits, you must add leading zeroes to total 11 digits.”

We’d like to provide additional details, as follows:

Many national drug codes are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs require a strategically placed zero, depending on the 10-digit format. The following table shows common 10-digit NDC formats indicated on packaging and the appropriate conversion to an 11-digit format. The correctly formatted additional “0” is in bold and underlined in the following examples.

Note: Hyphens indicated below are only used to illustrate the various formatting examples for NDCs. Do not use hyphens when entering the NDC in your claim.

10-digit format on package

10-digit format example

11-digit format

11-digit converted example

4-4-2

0002-7597-01
Zyprexa 10 mg vial

5-4-2

00002-7597-01

5-3-2

50242-040-62
Xolair 150 mg vial

5-4-2

50242-0040-62

5-4-1

60575-4112-1
Synagis 50 mg vial

5-4-2

60575-4112-01

None of the information included in this article should be considered legal advice. As such, it is the provider’s responsibility to ensure that all coding and documentation are done in accordance with applicable state and federal laws and regulations.


Pharmacy

Update: Report national drug code number on professional drug claims for accurate processing

National drug code information is now being used during the claims process to ensure the most accurate and up-to-date pricing for medical drugs, based on the date of service. This applies to all professional offices, clinics and practitioners who provide and bill medical drugs.

Other ancillary providers such as hemophilia network providers, home infusion therapy providers, ambulatory infusion centers, Walgreens Specialty Pharmacy, limited distribution drug specialty pharmacies and durable medical equipment providers are also required to provide the NDC information, as well as the quantity, for claims processing.

Note: Healthcare Common Procedure Coding System and Current Procedural Terminology® codes and quantities are required on all drug claims, as required by HIPAA.

The claims billing submissions information and formats described below can also be found in the provider manuals on web-DENIS.

Finding the NDC and unit of measure
The national drug code is found on a medication's packaging. An asterisk may appear as a placeholder for any leading zeroes. The container label also displays the appropriate unit of measure for that drug. The unit of measure is by weight (grams: GR), volume (milliliter: ML) or count (unit: UN). Each dispensed dose must be converted into one of these, following the manufacturer's unit of measure. International units (F2) must be converted to standard measurements (GR, ML and UN).

  • For drugs that come in a vial in powder form that needs to be reconstituted before administration, bill each vial (UN).
  • For drugs that comes in a vial in liquid form, bill in milliliters (ML).
  • For topical forms of medicine (e.g., cream, ointment, bulk powder in a jar), bill in grams (GR).

Submitting the NDC on claims
Here are some quick tips and general guidelines to assist you with proper submission of valid NDCs and related information on professional claims:

  • The NDC must be submitted along with the applicable HCPCS or CPT code.
  • The NDC must follow the “5digit4digit2digit” format (11 numeric characters with no spaces or special characters). The NDC must be active for the date of service.
  • To submit electronic claims (ANSI 837P), report the following information:

  • Field name

    Field description

    ANSI (Loop 2410) – Ref Desc

    Product ID Qualifier

    Enter “N4” in this field.

    LIN02

    National Drug CD

    Enter the 11-digit NDC assigned to the drug administered.

    LIN03

    NDC Units

    Enter the quantity (number of units) for the prescription drug.

    CTP04

    NDC Unit / MEAS

    Enter the unit of measure of the prescription drug given (GR, UN or ML).

    CTP05-1


  • To submit paper claims, enter the NDC information in field 24 of the CMS-1500 claim form. In the shaded portion of field 24A-24G, enter the qualifier “N4” left-justified, immediately followed by the national drug code. Next, enter the appropriate qualifier for the correct dispensing unit (GR, UN or ML), followed by the quantity and the price per unit, as indicated in the example below.

Here are two claims billing examples:

  • The format for billing should be:
    N4 + NDC code + 3 Spaces+ unit of measure + quantity
    Example: N450242005306   ML50

image 1

  • The format for billing should be:
    N4 + NDC code + 3 Spaces+ unit of measure + quantity
    Example: N468817013450   UN3

image 2 
Keep the following in mind:

  • Reimbursement for discarded drugs applies only to single-use vials. Discarded amounts of drugs in multi-use vials are not eligible for payment.
  • For home infusion therapy and specialty drugs, health care providers must continue to submit claims with national drug code and National Council for Prescription Drug Programs quantities electronically.
  • In previous articles, we mentioned the use of “ME” (milligrams); however, milligrams as a unit of measure will not be accepted.

BCBSM has also expanded the NDC quantity field to house 11 digits, which translates to 8 places before the decimal and 3 places after the decimal to large quantity units. Example: 99999999.999

Clarification: Converting an NDC from 10 to 11 digits
Previously, we communicated the following information about converting a 10-digit NDC to an 11-digit NDC: “If the NDC on the package label has fewer than 11 digits, you must add leading zeroes to total 11 digits.”

We’d like to provide additional details, as follows:

Many national drug codes are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs require a strategically placed zero, depending on the 10-digit format. The following table shows common 10-digit NDC formats indicated on packaging and the appropriate conversion to an 11-digit format. The correctly formatted additional “0” is in bold and underlined in the following examples.

Note: Hyphens indicated below are only used to illustrate the various formatting examples for NDCs. Do not use hyphens when entering the NDC in your claim.

10-digit format on package

10-digit format example

11-digit format

11-digit converted example

4-4-2

0002-7597-01
Zyprexa 10 mg vial

5-4-2

00002-7597-01

5-3-2

50242-040-62
Xolair 150 mg vial

5-4-2

50242-0040-62

5-4-1

60575-4112-1
Synagis 50 mg vial

5-4-2

60575-4112-01

None of the information included in this article should be considered legal advice. As such, it is the provider’s responsibility to ensure that all coding and documentation are done in accordance with applicable state and federal laws and regulations.


Medicare Advantage

BCBSM Medicare Advantage PPO home health care and skilled nursing facility audits begin this month

Starting this August, independent contractors will audit Blue Cross Blue Shield of Michigan Medicare Advantage home health care and skilled nursing facility claim payments.

These audits will be performed at the vendor’s office and modeled after the Centers for Medicare & Medicaid Services home health and skilled nursing facility audits. The contractors that will be performing the audits are HealthDataInsights and SCIO Health Analytics.

Home health care and skilled nursing facility services are defined as home health care services that occur within a BCBSM Medicare Advantage member’s home and are provided by home health care companies, including caregiver services, home health nursing, aides and therapists.

A skilled nursing facility provides health and therapeutic services to patients who require residential and continual nursing care. A licensed physician supervises each patient’s care and a nurse or other medical professional is almost always on the premises. Skilled nursing can be made available 24 hours a day.

Additional information will be included in letters sent to facilities.

If you have questions, contact your provider consultant or send an email to efoster@bcbsm.com.


My Advocate appointment scheduling underway

Member outreach initiatives are underway to encourage select Blue Cross Medicare Advantage members to schedule wellness visits with their physicians. Provider offices should expect an influx of calls from our members and the My Advocate appointment scheduling service.

My Advocate is a suite of member services offered by Altegra Health, an independent company that contracts with BCBSM to provide these services free of charge to our Medicare Advantage members.

These services include locating community programs that may save our members money on various health care needs, such as medical supplies, medications and everyday living expenses. The My Advocate program also provides education to our members on specific health issues and how to effectively communicate health concerns with their doctors.

We also encourage our members to visit their doctor regularly, take medications as prescribed and alert the appropriate doctor when issues arise. It’s our goal to provide our Medicare Advantage members with a quality service to aid them in maintaining their health without any additional out-of-pocket expenses.

What you need to know:

  • My Advocate will schedule appointments directly with your office staff while they have the member on the phone.
  • A confirmation fax will be sent to your office 24 to 48 hours prior to the member’s visit. The confirmation fax will include the member’s gaps in care and basic medical history.

Please notify your staff members of this outreach initiative in order to better prepare them for the increasing volume of calls and to create a pleasant experience for your patients over the next several weeks.


Blues Medicare Advantage website redesigned to improve customer experience

The Blues recently launched its redesigned Medicare website, bcbsm.com/medicare, to enhance the customer experience for people who shop for Medicare plans.

Key improvements include:

  • A new contemporary user interface
  • Information about Blue Cross Blue Shield of Michigan and Blue Care Network Medicare plans on one site
  • Simplified site navigation that makes it easier to find information about our Medicare plans
  • Easy-to-understand content
  • Faster and more effective search tools
  • A new Medicare 101 tutorial and help center that provide answers to the most commonly asked questions

The site’s helpful tools include:

  • The search tool on the home page. Just enter a simple keyword or phrase in the bar in the upper-right corner
  • The bottom of each page provides direct links to all the pages on the site.
  • The “contact us” link on each page has contact information for both group and individual members.

Over the next few months, the Blues’ Digital Experience team will work with Medicare business units to update the site in time for the 2015 enrollment period.

Site access is available to Medicare insurance shoppers, including those who are aging in, potential Medicare group customers, current members, providers, employers, agents and the general public.

If you have any problems accessing the site, call 1-877-258-3932.


Reminder: Submiting CMS-1500 claim forms for Medicare Advantage patients

To submit paper claims and avoid processing delays, BCBSM Medicare Advantage providers should send their CMS-1500 claim forms to:

Medicare Advantage
Blue Cross Blue Shield of Michigan
P.O. Box 32593
Detroit, MI 48232-0593

If you have any questions, please call your provider consultant.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2013 American Medical Association. All rights reserved.